Behavioral Study
Learn how the Libre 3 system drives behavior change and diabetes self-management in adults with T2D on basal or non-insulin treatment4.
Achieve better clinical outcomes*1-3.
Explore the clinical evidence behind continuous glucose monitors (CGMs)—the FreeStyle Libre systems.
Clinical Analyses
Explore key medical advancements and related patient outcomes.
GLP-1 Therapy
See how patients using a GLP-1 therapy experienced significant improvements in A1C after initiating Libre systems†5.
DSME = Diabetes Self-Management Education; GLP-1 = glucagon-like peptide-1; RCT = randomized controlled trial; T2D = type 2 diabetes
Case Studies
Discover how real patients benefit from using Libre systems and gain valuable, real-world insights.
Not actual image of user.
Debra, T2D patient:
See how the Libre 3 system helped Debra better understand her glucose levels, leading to improved medication adherence and TIR‡6.
Not actual image of user.
Joe, T2D patient:
Learn how the Libre 3 system helped Joe improve and maintain glycemic control even with GLP-1 interruption‡6.
GLP-1 = glucagon-like peptide-1; TIR = time in (target) range
Learn about Joe's diabetes management journey
Hear Dr. Paul share the journey of her patient, Joe, a T2D patient that used the Libre 3 system to improve and maintain glycemic control‡6.
American Diabetes Association (ADA) Guidelines
Join us at an upcoming event!
Mark your calendar to meet industry experts, connect with peers, and learn more about our latest innovations.
* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
† Real-world study that utilized a linked electronic health records (EHR)-claims database and included adults with T2D and HbA1C ≥8% who acquired their first GLP-1 2018–2022.
‡ Based on assessment and input from patient’s healthcare provider.
References: 1. Bolinder, Jan, et al. "Novel Glucose-Sensing Technology and Hypoglycaemia in Type 1 Diabetes: A Multicentre, Non-Masked, Randomised Controlled Trial." The Lancet 388, no. 10057 (2016): 2254–2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 2. Evans, Mark, Zoë Welsh, and Alexander Seibold. “Reductions in HbA1C with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies.” Diabetes Therapy 13, no. 6 (2022): 1175–1185. https://doi.org/10.1007/s13300-022-01253-9. 3. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: A Multicentre, Open-Label Randomised Controlled Trial." Diabetes Therapy 8 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 4. Polonsky, William H., et al. “How CGM Use in Adults with Type 2 Diabetes Leads to Glycemic Benefits: The Role of Medication and Behaviour Change.” Endocrinology, Diabetes & Metabolism 9, no. 3 (2026). https://doi.org/10.1002/edm2.70236. 5. Miller, Eden, et al. “Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.” Diabetes Therapy 15 (2024): 2027–2038. https://doi.org/10.1007/s13300-024-01619-1. 6. Data on file. Abbott Diabetes Care, Inc.
ADC-2666161 v4.0
Important Safety Information
Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Get medical attention when appropriate. Abbott Customer Service at 855-632-8658 or visit FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-2688941 v26.0
